Role of preoperative transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (Hong Kong liver cancer stage IIB).

Abstract

Transarterial chemoembolization (TACE) has an established role in advanced HCC. The present study evaluates the role of TACE as a neoadjuvant modality in the management of intermediate HCC [Hong Kong Liver Cancer (HKLC) stage IIB]. A retrospective analysis of HCC patients treated between January 2010 and August 2022 was performed. Patients belonging to intermediate-stage HCC (HKLC IIB) were divided into two groups, upfront surgery (UPS) and post-TACE (pTACE). Propensity score matching was done, and the primary endpoint of the study was overall survival (OS). A total of 247 patients of HKLC IIB were identified during this period. Of these, 77 patients in each group were considered for analysis after propensity matching. The median follow-up was 36.4 months (0.46-144.26). In the propensity matched population (n = 154), on an intention-to-treat analysis, the median OS of the UPS group and the pTACE group was 30.06 and 39.26 months, respectively (p value = 0.77). In patients who underwent curative resection, the median OS of the UPS group was 30.68 versus 90.97 months in the pTACE group (p value = 0.006) and median DFS was 13.56 months for the UPS group versus 44.02 months in the pTACE group, respectively (p value = 0.013). In intermediate-stage hepatocellular carcinoma (HKLC IIB), pTACE can be used to better select patients with borderline resectability. Survival was significantly improved in patients who received pTACE and were able to undergo surgical resection.